Cargando…

ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways

Consumption of a high fat diet (HFD) is linked to metabolic syndrome and cognitive impairments. This is exacerbated in age-related cognitive decline (ACD) and in individuals with a genetic risk for Alzheimer’s disease (AD). Apolipoprotein E (apoE) is involved in cholesterol metabolism. In humans, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kundu, Payel, Holden, Sarah, Paraiso, Ines L., Sudhakar, Reetesh, McQuesten, Chloe, Choi, Jaewoo, Miranda, Cristobal L., Maier, Claudia S., Bobe, Gerd, Stevens, Jan F., Raber, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583926/
https://www.ncbi.nlm.nih.gov/pubmed/36278228
http://dx.doi.org/10.3389/fphar.2022.954980
_version_ 1784813176717574144
author Kundu, Payel
Holden, Sarah
Paraiso, Ines L.
Sudhakar, Reetesh
McQuesten, Chloe
Choi, Jaewoo
Miranda, Cristobal L.
Maier, Claudia S.
Bobe, Gerd
Stevens, Jan F.
Raber, Jacob
author_facet Kundu, Payel
Holden, Sarah
Paraiso, Ines L.
Sudhakar, Reetesh
McQuesten, Chloe
Choi, Jaewoo
Miranda, Cristobal L.
Maier, Claudia S.
Bobe, Gerd
Stevens, Jan F.
Raber, Jacob
author_sort Kundu, Payel
collection PubMed
description Consumption of a high fat diet (HFD) is linked to metabolic syndrome and cognitive impairments. This is exacerbated in age-related cognitive decline (ACD) and in individuals with a genetic risk for Alzheimer’s disease (AD). Apolipoprotein E (apoE) is involved in cholesterol metabolism. In humans, there are three major isoforms, E2, E3, and E4. Compared to E3, E4 increases ACD and AD risk and vulnerability to the deleterious cognitive effects of a HFD. The plant compound Xanthohumol (XN) had beneficial effects on cognition and metabolism in C57BL/6J wild-type (WT) male mice put on a HFD at 9 weeks of age for 13 weeks. As the effects of XN in the context of a HFD in older WT, E3, and E4 female and male mice are not known, in the current study male and female WT, E3, and E4 mice were fed a HFD alone or a HFD containing 0.07% XN for 10 or 19 weeks, starting at 6 months of age, prior to the beginning of behavioral and cognitive testing. XN showed sex- and ApoE isoform-dependent effects on cognitive performance. XN-treated E4 and WT, but not E3, mice had higher glucose transporter protein levels in the hippocampus and cortex than HFD-treated mice. E3 and E4 mice had higher glucose transporter protein levels in the hippocampus and lower glucose transporter protein levels in the cortex than WT mice. In the standard experiment, regardless of XN treatment, E4 mice had nearly double as high ceramide and sphingomyelin levels than E3 mice and male mice had higher level of glycosylated ceramide than female mice. When the differential effects of HFD in E3 and E4 males were assessed, the arginine and proline metabolism pathway was affected. In the extended exposure experiment, in E3 males XN treatment affected the arginine and proline metabolism and the glycine, serine, and threonine metabolism. Myristic acid levels were decreased in XN-treated E3 males but not E3 females. These data support the therapeutic potential for XN to ameliorate HFD-induced cognitive impairments and highlight the importance of considering sex and ApoE isoform in determining who might most benefit from this dietary supplement.
format Online
Article
Text
id pubmed-9583926
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95839262022-10-21 ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways Kundu, Payel Holden, Sarah Paraiso, Ines L. Sudhakar, Reetesh McQuesten, Chloe Choi, Jaewoo Miranda, Cristobal L. Maier, Claudia S. Bobe, Gerd Stevens, Jan F. Raber, Jacob Front Pharmacol Pharmacology Consumption of a high fat diet (HFD) is linked to metabolic syndrome and cognitive impairments. This is exacerbated in age-related cognitive decline (ACD) and in individuals with a genetic risk for Alzheimer’s disease (AD). Apolipoprotein E (apoE) is involved in cholesterol metabolism. In humans, there are three major isoforms, E2, E3, and E4. Compared to E3, E4 increases ACD and AD risk and vulnerability to the deleterious cognitive effects of a HFD. The plant compound Xanthohumol (XN) had beneficial effects on cognition and metabolism in C57BL/6J wild-type (WT) male mice put on a HFD at 9 weeks of age for 13 weeks. As the effects of XN in the context of a HFD in older WT, E3, and E4 female and male mice are not known, in the current study male and female WT, E3, and E4 mice were fed a HFD alone or a HFD containing 0.07% XN for 10 or 19 weeks, starting at 6 months of age, prior to the beginning of behavioral and cognitive testing. XN showed sex- and ApoE isoform-dependent effects on cognitive performance. XN-treated E4 and WT, but not E3, mice had higher glucose transporter protein levels in the hippocampus and cortex than HFD-treated mice. E3 and E4 mice had higher glucose transporter protein levels in the hippocampus and lower glucose transporter protein levels in the cortex than WT mice. In the standard experiment, regardless of XN treatment, E4 mice had nearly double as high ceramide and sphingomyelin levels than E3 mice and male mice had higher level of glycosylated ceramide than female mice. When the differential effects of HFD in E3 and E4 males were assessed, the arginine and proline metabolism pathway was affected. In the extended exposure experiment, in E3 males XN treatment affected the arginine and proline metabolism and the glycine, serine, and threonine metabolism. Myristic acid levels were decreased in XN-treated E3 males but not E3 females. These data support the therapeutic potential for XN to ameliorate HFD-induced cognitive impairments and highlight the importance of considering sex and ApoE isoform in determining who might most benefit from this dietary supplement. Frontiers Media S.A. 2022-10-03 /pmc/articles/PMC9583926/ /pubmed/36278228 http://dx.doi.org/10.3389/fphar.2022.954980 Text en Copyright © 2022 Kundu, Holden, Paraiso, Sudhakar, McQuesten, Choi, Miranda, Maier, Bobe, Stevens and Raber. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Kundu, Payel
Holden, Sarah
Paraiso, Ines L.
Sudhakar, Reetesh
McQuesten, Chloe
Choi, Jaewoo
Miranda, Cristobal L.
Maier, Claudia S.
Bobe, Gerd
Stevens, Jan F.
Raber, Jacob
ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways
title ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways
title_full ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways
title_fullStr ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways
title_full_unstemmed ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways
title_short ApoE isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways
title_sort apoe isoform-dependent effects of xanthohumol on high fat diet-induced cognitive impairments and hippocampal metabolic pathways
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583926/
https://www.ncbi.nlm.nih.gov/pubmed/36278228
http://dx.doi.org/10.3389/fphar.2022.954980
work_keys_str_mv AT kundupayel apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT holdensarah apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT paraisoinesl apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT sudhakarreetesh apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT mcquestenchloe apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT choijaewoo apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT mirandacristoball apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT maierclaudias apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT bobegerd apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT stevensjanf apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways
AT raberjacob apoeisoformdependenteffectsofxanthohumolonhighfatdietinducedcognitiveimpairmentsandhippocampalmetabolicpathways